Japan's Mochida Pharma To Expand Generic, Biosimilar Cancer Business
This article was originally published in PharmAsia News
Executive Summary
Mochida Pharmaceutical plans to expand its generics and biosimilars lines with an eye on building a $110.2 million-a-year business over the next three years, a rate double this year's expected earnings.
You may also be interested in...
Showcasing Its Pandemic Response Drug Discovery, Berkeley Lights Prepares For IPO
Chief executive Eric Hobbs talks about the technology needed to accelerate antibody, cell therapy and synthetic biology, and prepare for the next pandemic.
Probiotics’ Efficacy Too Specific For General Look In ’60 Minutes’ Segment Critical Of Category
A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.
Stada Will Continue To Invest To Drive Growth
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Need a specific report? 1000+ reports available
Buy Reports